Fairvalue-Calculator Fairvalue-Calculator
EN DE

METACARE CO., Ltd (118000) Fair Value & Analysis

Healthcare · KR · Market cap 25.1B KRW

Price1,243 KRW
Fair Value638.12 KRW
Upside-48.7%
Quality94/100
Evidence: Medium Range 478.59 KRW – 797.65 KRW

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

METACARE CO., Ltd (118000) currently trades at 1,243 KRW, while our model-based Fair Value estimate is 638.12 KRW — implying the stock looks roughly 48.7% overvalued today. We read business quality at 94/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

About the company

METACARE CO., Ltd. distributes pharmaceuticals and medical devices in South Korea. The company sells orthopedic medical devices and consumables; and provides pharmaceutical integration and professional logistics services. It is involved in investment advisory. The company was formerly known as SMEDI Co., Ltd. and changed its name to METACARE CO., Ltd. in August 2024. METACARE CO., Ltd. was founded in 2009 and is headquartered in Hwaseong-si, South Korea.

Open the full interactive analysis →

Similar stocks

Eli Lilly and Company (LLY) -64% Johnson & Johnson, (JNJ) -29% AbbVie Inc (ABBV) -42% Roche Holding (ROGN) -4% Merck & Co (MRCK34) -35% AstraZeneca PLC (A1ZN34) -31%

Frequently asked questions

Is METACARE CO., Ltd (118000) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 638.12 KRW versus a price of 1,243 KRW — about −49% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 118000?
Our 21-model fair value for METACARE CO., Ltd is 638.12 KRW (as of Jun 24, 2026), built from audited fundamentals. The current price is 1,243 KRW.
What is the quality score of 118000?
METACARE CO., Ltd has a Quality Score of 94/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.